Free Trial

Design Therapeutics (DSGN) Competitors

Design Therapeutics logo
$3.92 -0.12 (-2.97%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$3.92 0.00 (0.00%)
As of 07/11/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DSGN vs. OCS, CMRX, CDMO, QURE, CRMD, CRON, GHRS, SNDX, IMNM, and GYRE

Should you be buying Design Therapeutics stock or one of its competitors? The main competitors of Design Therapeutics include Oculis (OCS), Chimerix (CMRX), Avid Bioservices (CDMO), uniQure (QURE), CorMedix (CRMD), Cronos Group (CRON), GH Research (GHRS), Syndax Pharmaceuticals (SNDX), Immunome (IMNM), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry.

Design Therapeutics vs. Its Competitors

Oculis (NASDAQ:OCS) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Design Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -13,788.70%. Design Therapeutics' return on equity of -22.85% beat Oculis' return on equity.

Company Net Margins Return on Equity Return on Assets
Oculis-13,788.70% -92.95% -70.03%
Design Therapeutics N/A -22.85%-22.02%

22.3% of Oculis shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 31.2% of Design Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Oculis had 2 more articles in the media than Design Therapeutics. MarketBeat recorded 4 mentions for Oculis and 2 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.93 beat Oculis' score of 0.47 indicating that Design Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oculis
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Design Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Oculis has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500.

Oculis currently has a consensus price target of $35.33, suggesting a potential upside of 95.64%. Design Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 2.04%. Given Oculis' stronger consensus rating and higher possible upside, research analysts plainly believe Oculis is more favorable than Design Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oculis
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Design Therapeutics
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Design Therapeutics has lower revenue, but higher earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oculis$780K1,010.90-$97.43M-$2.64-6.84
Design TherapeuticsN/AN/A-$49.59M-$0.99-3.96

Summary

Design Therapeutics beats Oculis on 10 of the 15 factors compared between the two stocks.

Get Design Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DSGN vs. The Competition

MetricDesign TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$229.35M$2.99B$5.60B$9.11B
Dividend YieldN/A2.39%5.24%4.02%
P/E Ratio-3.9620.5827.9620.25
Price / SalesN/A292.00430.8999.65
Price / CashN/A42.8637.4658.16
Price / Book0.927.638.045.49
Net Income-$49.59M-$55.05M$3.18B$250.27M
7 Day Performance3.98%8.39%3.63%4.75%
1 Month Performance0.26%5.35%4.04%7.64%
1 Year Performance-10.09%1.95%29.55%16.34%

Design Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DSGN
Design Therapeutics
0.6315 of 5 stars
$3.92
-3.0%
$4.00
+2.0%
-7.5%$229.35MN/A-3.9640News Coverage
OCS
Oculis
2.1969 of 5 stars
$18.74
-1.4%
$35.33
+88.5%
+58.4%$829.58MN/A-7.102News Coverage
CMRX
Chimerix
0.5467 of 5 stars
$8.54
flat
$8.53
-0.1%
N/A$801.09M$212K-9.0990
CDMO
Avid Bioservices
0.6156 of 5 stars
$12.50
+0.1%
$12.25
-2.0%
+56.2%$799.18M$139.91M-5.23320News Coverage
High Trading Volume
QURE
uniQure
2.714 of 5 stars
$14.31
-0.8%
$37.82
+164.3%
+61.6%$789.86M$27.12M-3.26500
CRMD
CorMedix
2.7217 of 5 stars
$11.42
-1.7%
$17.14
+50.1%
+128.5%$788.13M$82.55M51.9130Positive News
CRON
Cronos Group
1.5748 of 5 stars
$2.04
flat
N/A-12.2%$786.79M$117.61M15.69450News Coverage
GHRS
GH Research
1.9761 of 5 stars
$15.01
+0.7%
$32.00
+113.2%
+33.4%$776MN/A-19.0010
SNDX
Syndax Pharmaceuticals
3.0276 of 5 stars
$8.73
-3.0%
$35.80
+310.1%
-59.2%$774.43M$23.68M-2.26110Analyst Forecast
IMNM
Immunome
2.0818 of 5 stars
$8.69
-1.7%
$23.33
+168.5%
-33.4%$769.19M$9.04M-2.7340Positive News
GYRE
Gyre Therapeutics
0.2281 of 5 stars
$7.62
-6.3%
N/A-40.6%$762.25M$105.76M381.1940Positive News

Related Companies and Tools


This page (NASDAQ:DSGN) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners